Technology for Clinical Management of Oxidative Stress
1 R43 MH53810-01,
We will develop technology for assessing and managing oxidative stress in neurodegenerative disordePhase I aims are defining urine plasma levels of twelve proposed purine, hydroxyl, and nitrohydroxyspectrum of neurodegenerative diseases; evaluating challenge tests for over production and under prooxygen species; investigating simplified sample acquisition analysis protocols for clinical laboratoapplying new electrochemical technology for monitoring oxidative capacity. Methodology for existingElectrode Array Systems (CEAS) with new adjunct technology for contaminant suppression and reactivestabilization allows simultaneous resolution of twelve currently proposed oxidative stress markers foxidizable species. Unique properties of treated porous graphites allow the potential simplificatioacquisition and assay and an integrated sampler sensor disposable derived from blood lead analysis tused to measure total oxidative capacity. The works technical and commercial significance lies in detechnological improvements in chromatographic methodology for the research market; broadening the apintegrated sampler/sensor technology for on site monitoring and a new disposable kit and assay for tlaboratory market.
Small Business Information at Submission:
Principal Investigator:Wayne Matson
45 Wiggins Avenue Bedford, MA 01730
Number of Employees: